-
A Néoplasma of the Breast Revealed by a Bilateral Choriodal Metasytasis
Souhail Hassane,
Ifrkhas Said,
Laktaoui Abdelkader
Issue:
Volume 3, Issue 3, May 2015
Pages:
28-31
Received:
27 March 2015
Accepted:
31 March 2015
Published:
10 April 2015
Abstract: The uveals metastases are the most frequent malignant tumours of the eye, 10 times more than the melanoma. Their rate of which has occurred is estimated in the recent literature between 2 and 38%, their period of apparition are more often at the final stage of the neoplasma. Our work present the rare case of 40 year old patient, in quite condition general, addressed to our consultation for bilateral retinal detachment, whose clinical exams, angiographic, B-scan, CT-tomography and mammography make it possible to keep the diagnosis of bilateral uveal metastasis revealing an unrecognised néoplasma of the breast to the stage of bony and ganglial metastasis. Knowing the severe prognosis of uveal metastasis, a suitable treatment is started trying as well as possible to preserve the visual prognosis in this patient suffering of cancer.
Abstract: The uveals metastases are the most frequent malignant tumours of the eye, 10 times more than the melanoma. Their rate of which has occurred is estimated in the recent literature between 2 and 38%, their period of apparition are more often at the final stage of the neoplasma. Our work present the rare case of 40 year old patient, in quite condition ...
Show More
-
Bevacizumab Induced Cardiomyopathy in a Patient with Adult Congenital Heart Disease: A Case Report and Brief Review
Hemalatha Narayanasamy,
Nikky Bardia,
Michael Fong,
Luanda Grazette
Issue:
Volume 3, Issue 3, May 2015
Pages:
32-36
Received:
3 March 2015
Accepted:
23 March 2015
Published:
21 April 2015
Abstract: Background: Cardiac dysfunction is an unusual but documented side effect of many forms of antineoplastic therapy. Bevacizumab is a novel antineoplastic agent that inhibits VEGF-A with a low reported incidence of cardiotoxicity (1.7 - 3%) derived primarily from clinical trials of women with breast cancer which captured adverse events of symptomatic heart failure. Subsequent studies suggest the incidence of asymptomatic decline in cardiac function may be closer to 20%. Untreated declines in cardiac function are associated with increased morbidity and mortality, early recognition and treatment can improve outcomes. Case Report: Here we describe a case of a 51 year old male being treated with Bevacizumab for metastatic neuroendocrine cancer of the colon who developed a severe asymptomatic decline in cardiac function. With interruption of Bevacizumab and implementation of heart failure therapy his cardiac function returned to baseline. Conclusion: Early recognition and application of heart failure disease modifying therapy can decrease the risk and improve the likelihood of recovery in cases of chemotherapy induced cardiac dysfunction. Baseline cardiac testing and standardized surveillance can increase the opportunities for early intervention and may improve long term outcomes.
Abstract: Background: Cardiac dysfunction is an unusual but documented side effect of many forms of antineoplastic therapy. Bevacizumab is a novel antineoplastic agent that inhibits VEGF-A with a low reported incidence of cardiotoxicity (1.7 - 3%) derived primarily from clinical trials of women with breast cancer which captured adverse events of symptomatic ...
Show More
-
The Complete Decongestive Therapy to Treat Lymphedema in Post-Breast Cancer Surgery and Its Relationships with Patients Psychological and Physical Characteristics: A Pilot Study
Eva Mazzotti,
Roberto Bartoletti,
Claudia Sebastiani,
Alessandro Scoppola,
Paolo Marchetti
Issue:
Volume 3, Issue 3, May 2015
Pages:
37-41
Received:
10 November 2014
Accepted:
6 January 2015
Published:
30 April 2015
Abstract: Background. More than 20% of women treated for breast cancer are at risk for developing lymphedema, a chronic condition that causes swelling, pain, altered appearance and reduced mobility. Complete Decongestive Therapy (CDT) is considered the gold standard to treat lymphedema. Objective. To measure lymphedema features and psychological variables in 10 post-breast cancer surgery patients at baseline, and 1, 6, and 12 months after CDT. Results. Lymphedema appeared between 0 and 6 years after breast cancer surgery. After 4 weeks in CDT treatment, the median degree of reduction was 38.73% (range, 7.45-58.39), and six months after, 49.57% (range, 11.91-82.50). Comparing patients that have had an extra reduction in arm circumferences at T3 (group 1) and patients that did not (group 2), we found: patients in group 1 showed at baseline a better psychological functioning (health-related quality of life domains, anxiety, depression, body-image vulnerability, appearance stereotyping), and higher scores in curability and severity respect to the comparison group. 12 months after the CDT, among patients of the group 1, the lymphedema is perceived as less severe and more curable compared to their perception at baseline, and dysfunctional investment in one’s appearance and anxiety scores decreased, emotional wellbeing improved. Patients in the group 2 perceived lymphedema as much more curable, but also much more severe that at baseline. Both, anxiety and dysfunctional investment in one’s appearance scores increased. Conclusions. Too often, conventional rehabilitation may not optimally match clinical resources to patients’ needs, and if our results will be confirmed, screening and independent treatment for psychological distress will be required in patients to prevent poor CDT responses.
Abstract: Background. More than 20% of women treated for breast cancer are at risk for developing lymphedema, a chronic condition that causes swelling, pain, altered appearance and reduced mobility. Complete Decongestive Therapy (CDT) is considered the gold standard to treat lymphedema. Objective. To measure lymphedema features and psychological variables in...
Show More
-
Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
Kweon Sang Moon,
Joo Yeon Ji,
Yoo Jin Cho,
Jong Hwa Lee,
Myung Sup Choi,
Euishin Edmund Kim
Issue:
Volume 3, Issue 3, May 2015
Pages:
42-46
Received:
4 March 2015
Accepted:
29 May 2015
Published:
4 July 2015
Abstract: Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.
Abstract: Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of...
Show More
